Vida Ventures Advisors’s Dyne Therapeutics DYN Stock Holding History

Vida Ventures Advisors’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-407,499	Closed	-$9.6M	–	5
2024 Q4	$9.6M	Hold	407,499	–	–	6.56%	4
2024 Q3	$14.6M	Hold	407,499	–	–	10.56%	4
2024 Q2	$14.4M	Hold	407,499	–	–	15.73%	3
2024 Q1	$11.6M	Sell	407,499 -1,667,288	-80%	-$37.7M	6.43%	3
2023 Q4	$27.6M	Sell	2,074,787 -145,247	-7%	-$1.42M	32.85%	2
2023 Q3	$19.9M	Hold	2,220,034	–	–	30.79%	2
2023 Q2	$25M	Hold	2,220,034	–	–	32.61%	1
2023 Q1	$25.6M	Hold	2,220,034	–	–	34.99%	1
2022 Q4	$25.7M	Hold	2,220,034	–	–	34.58%	1
2022 Q3	$28.2M	Sell	2,220,034 -740,012	-25%	-$8.48M	25.3%	1
2022 Q2	$20.3M	Hold	2,960,046	–	–	17.18%	3
2022 Q1	$28.5M	Hold	2,960,046	–	–	16.6%	4
2021 Q4	$35.2M	Hold	2,960,046	–	–	13.17%	5
2021 Q3	$48.1M	Hold	2,960,046	–	–	13.77%	5
2021 Q2	$62.3M	Hold	2,960,046	–	–	15.62%	4
2021 Q1	$46M	Hold	2,960,046	–	–	11.61%	5
2020 Q4	$62.2M	Hold	2,960,046	–	–	12.76%	4
2020 Q3	$59.8M	Buy	+2,960,046	New	+$65M	37.43%	2

Other funds holding DYN

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vida Ventures Advisors's DYN Position: Q1 2025 in Review

Vida Ventures Advisors sold out of Dyne Therapeutics (DYN) in Q1 2025, closing a stake of 407,499 shares — an estimated $9.6M sold.

Vida Ventures Advisors first reported a position in DYN in Q3 2020 and held it in 18 quarters. The position peaked at $62.3M in Q2 2021. 205 funds tracked by Wall St. Rank hold DYN as of Q1 2025.

Vida Ventures Advisors reported no remaining Dyne Therapeutics position as of Q1 2025 after selling out during the quarter.
Vida Ventures Advisors sold 407,499 Dyne Therapeutics shares in Q1 2025, an estimated $9.6M.
Vida Ventures Advisors first reported a position in Dyne Therapeutics in Q3 2020 and held it in 18 quarters.
Vida Ventures Advisors's Dyne Therapeutics position peaked at $62.3M in Q2 2021.
205 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2025.

Based on Vida Ventures Advisors's 13F filing for Q1 2025, filed 3 Apr 2025.